🇺🇸

US SEC Filing Intelligence

· daily

US Merger & Acquisition SEC Filings — April 22, 2026

The 11 filings highlight intense SPAC lifecycle activity in US M&A, with 1 fresh $100M IPO (QuasarEdge), 3 advancing business combinations (Iron Horse $250M+ AI battery deal, Allegro warrant support for SeeQC merger, Constellation HiTech webinar), 4 deadline extensions/postponements (TLGY to July 2026, Pyrophyte trust at $19.5M seeking further extension, SIM EGM delayed to May 1 2026, Everest interest withdrawal amendment), 1 merger termination (Oak Woods), 1 Nasdaq compliance risk (Flag Ship late 10-K), and 1 completed takeover (First Eagle acquires Diamond Hill at $175/share, pro forma AUM $213B). No operational revenue/margin trends available as most are pre-revenue SPACs, but trust account stability is key metric with Pyrophyte at $12.91/share redemption value and full extension deposits made. Positive themes dominate in tech/AI/minerals deals amid prolonged searches, but risks of liquidation/Nasdaq delisting loom for laggards. Portfolio-level pattern: 7/11 filings show extension efforts or new capital (vs 2 failures), implying sector resilience but extended timelines to H2 2026/2027 closings. Market implication: Opportunities in de-SPAC targets like Electra AI battery (backed by Stellantis/Ferrari), while monitor redemptions and compliance.

11 high priority 11 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 22, 2026

Overnight SEC filings reveal a bullish tilt in industrials and healthcare with standout Q1 beats from Vertiv (+30% YoY sales, raised FY guidance), Monarch Casino (record +8.9% revenue, +38.9% net income), and Elevance Health (raised FY EPS to $26.75+ despite CMS accrual hit), contrasting mixed results at Otis Worldwide (+6% sales but -130 bps margins) and ongoing losses at Gaotu Techedu (+35% revenue YoY but net loss $46M). Healthcare shines with National Healthcare's $560M accretive acquisition (Q3 2026 close) and Kyverna's positive KYSA-8 trial data (conference call April 22), while HIVE Digital upsized $100M notes offering for GPU expansion. Capital allocation remains shareholder-friendly: Otis $400M buybacks, Elevance $5.6B repurchase authorization, Monarch $17.6M repurchases + $0.30 dividend. 13F filings (22 total) show institutional stability in ETFs/tech giants (e.g., NVDA, Apple across multiple managers), no major shifts. SPAC activity mixed: Oak Woods merger termination bearish, Archimedes/Forge Nano merger announced. Portfolio-level: 5/7 earnings reporters grew revenue >6% YoY (avg +18%), but margins compressed in 2/5 (-130 to -240 bps); watch guidance catalysts pre-market.

11 high priority 39 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 21, 2026

Across 20 filings in the USA S&P 500 Technology stream (with cross-sector context), key themes include robust revenue growth in tech leaders like Intuitive Surgical (+23% YoY) and CrowdStrike (revenue +57% FY2024-2026, ARR +52%), contrasted by pressures in healthcare (Community Health Systems rev -6.1% YoY, net loss widened to $(0.43)/share). Financial institutions showed YoY strength (United Community Banks NI +18%, Community Bancorp +24%) amid NIM expansions (+29 bps for UCB) and accretive M&A, while capital returns accelerated via Adobe's $25B buyback authorization (through 2030), Mueller's 40% dividend hike and $75M repurchases, and UCB's share buybacks. Period-over-period trends reveal 7/12 reporting companies with double-digit YoY revenue gains averaging +20%, but QoQ softness in banks and operating cash declines (Mueller -30%). Insider alignment positive via CrowdStrike's 100K PSU award to President (tied to 3-year TSR vs S&P 500, up to 200% payout), no notable selling. Forward-looking catalysts include UCB-Peach State merger ($0.09 EPS accretion 2027), CRWD's $20B ARR ambition by 2028, and multiple AGMs/proxies in June. Portfolio implication: overweight growth tech with buyback support, monitor bank M&A regulatory risks.

7 high priority 13 medium 20 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 21, 2026

Across 26 NASDAQ-100 related filings dated April 21, 2026, regional banks like United Community Banks (UCB) and Community Bancorp showcased robust Q1 results with net income up 18-24% YoY, NIM expansion (+29 bps YoY for UCB), and loan/deposit growth, alongside M&A activity including UCB's $100M Peach State acquisition at 1.9x TBV expecting $0.09 EPS accretion in 2027. Tech and industrials leaders reported strong growth: Intuitive Surgical revenue +23% YoY on 17% procedure growth, Mueller Industries sales +19% YoY amid copper price surge, and Adobe authorized $25B buyback through 2030. Healthcare showed divergence with Community Health Systems revenues down 6.1% YoY and Adjusted EBITDA -18% due to divestitures, contrasting positive operational metrics elsewhere. Capital allocation trends favor shareholders with repurchases (UCB 1.09M shares, Mueller 650k shares, Adobe $25B program) and dividend hikes (Mueller +40% to $0.35, Community Bancorp $0.25). Mixed sentiments prevail in speculative names like Faraday Future (financing but 45% share increase sought) and Broadcom (AGM dissent on comp/director). Portfolio-level, 5/7 financials exhibited YoY net income growth averaging +20%, signaling sector resilience, while forward catalysts cluster around June AGMs and merger approvals.

8 high priority 18 medium 26 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 21, 2026

Across 50 filings from S&P 500 Financials and related streams, dominant themes include robust institutional portfolio tilts toward tech megacaps (Apple, MSFT, NVDA appearing in 20+ 13F-HR filings) and ETFs, signaling conviction in growth amid volatility; strong capital allocation in financial services with Synchrony Financial launching $6.5B buyback and 13% dividend hike, UnitedHealth targeting $2B repurchases by Q2-end, and News Corp's $1B program. Period-over-period trends show mixed resilience: Synchrony Q1 net earnings +6% YoY to $805M with NCOs -96bps to 5.42%, UnitedHealth revenues +2% YoY but Optum dip QoQ, First United NI +16% YoY to $6.7M and NIM + to 3.83%, though loans flat/declining in banks. SPAC activity surges with $1.2B Forge Nano merger, $303M Key Mining deal, and multiple IPO filings, highlighting M&A catalysts. Forward-looking positives include UnitedHealth's FY2026 EPS guidance >$18.25 (raised), Synchrony's monthly stats continuity, and accretive deals like Onto Innovation's $710M Rigaku stake. Overall, financials exhibit margin stability and shareholder returns amid flat lending, but SPACs and 13Fs point to broader equity optimism; risks cluster in covenant waivers (Inotiv) and prelim losses (Allbirds). Portfolio-level: 30+ 13Fs aggregate $10T+ AUM with 40%+ tech/ETF exposure, avg unchanged QoQ.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 21, 2026

Across 50 SEC filings from diverse sectors (despite Consumer Staples focus, dominated by industrials, financials, REITs, and biotechs), Q1 2026 results show robust revenue growth averaging +15-25% YoY in reporting companies like GE Aerospace (+25%), Zurn Elkay (+11%), and Valmont (+6%), but margin compression in 4/7 key earners (e.g., GE -490 bps GAAP, Aerospace -230 bps). Capital allocation remains shareholder-friendly with dividends (Delek $0.255/share, Armour $0.24/share, Valmont +13% to $0.77) and buybacks (Zurn $50M, Donnelley $150M new program, Valmont $57.5M Q1). Positive M&A/licensing (NEXGEL triples revenue pro-forma to $35M) and financings (Prelude $90M raise) offset risks like operational disruptions (Aspen explosion) and partnership terminations (Rigel with Lilly). Forward guidance largely maintained or raised (GE full-year EPS $7.10-$7.40, Valmont $21.50-$23.50, Zurn Q2 8-9% growth), signaling resilience; institutional 13Fs (e.g., Pinnacle, Morton Brown) show heavy tech/ETF tilts with no major shifts. Proxy-heavy filings highlight governance refreshes and compensation approvals, with mixed sentiment (25% positive, 30% mixed, 45% neutral). Portfolio-level: 6/10 key filers grew EPS YoY, but 3 saw loan/asset declines; watch Q1 earnings catalysts Apr 22-25 for guidance updates amid tariff risks.

17 high priority 33 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 21, 2026

Across 50 filings in the USA S&P 500 Industrials stream (April 21, 2026), dominant themes include robust revenue growth in defense and aerospace (e.g., GE +25% YoY, RTX +9% YoY organic, Northrop +4% YoY) offset by margin compression (GE profit margin -490 bps, RTX segment mix issues), mixed bank earnings irrelevant to core industrials but showing NIM expansion (Peoples 4.16%, United 3.65% +29 bps YoY), and heightened SPAC/M&A activity in adjacent tech/housing (Boxabl merger, Forge Nano $1.2B deal). Period-over-period trends reveal 7/10 key industrials with YoY revenue growth averaging +15% but operating margins down avg -150 bps due to costs/tariffs; capital returns strong with buybacks (Tractor Supply $118M) and dividends (Delek $0.255/share). Forward guidance largely reaffirmed or raised (RTX EPS to $6.70-6.90, Danaher to $8.35-8.55), signaling conviction amid sector rotation. 13F filings (20+) show heavy industrials exposure (e.g., Caterpillar top in Independent Wealth $18.5M, Generali Freeport-McMoRan $52M), indicating institutional accumulation. SPAC resurgences in quantum/housing flag construction/aerospace adjacency opportunities, while pharma filings (Tarsier IPO, Genprex trials) suggest biotech crossover. Overall, bullish on defense backlog growth ($95B Northrop) but cautious on industrial cost pressures; actionable now: overweight RTX/GE pre-guidance catalysts.

12 high priority 38 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 21, 2026

Across the 8 filings in the USA S&P 500 Energy intelligence stream, core Energy players like Halliburton and Devon Energy show mixed performance: Halliburton doubled Q1 2026 net income YoY to $461M despite flat $5.4B revenue and segment declines, while Devon exceeded 2025 FCF ($2.56B vs $2.5B target) and production targets (840 MBOE/d vs 823) but posted -13% YoY FCF decline amid a pending Coterra merger. Institutional 13F filings from Williams & Novak and Stokes Capital reveal neutral, diversified portfolios heavy in ETFs with minimal Energy exposure. Non-Energy filings highlight growth in Interactive Brokers (17% YoY revenue to $1.67B), a SPAC IPO by Hall Chadwick aiming for $265M raise, positive board addition at Howard Hughes, and neutral severance tweaks at Robert Half. Overarching themes include resilient profitability in Energy services amid flat revenues, M&A catalysts like Devon's Feb 1, 2026 Coterra deal, steady capital returns (Halliburton $100M buybacks + $142M dividends), and neutral institutional conviction. Portfolio-level trends show international offset for North America weakness in Energy (Halliburton Int'l +3% vs NA -4%), signaling sector rotation opportunities. Critical implications: Monitor Energy M&A and Q2 catalysts for alpha amid geopolitical drags.

3 high priority 5 medium 8 total filings
· daily

US Material Events SEC 8-K Filings — April 21, 2026

Across 50 8-K filings from April 21, 2026, M&A activity dominates with 12+ deals totaling $3B+ in value, spanning AI (SoundHound-LivePerson $250M EV), industrials (Brady-Honeywell PSS $1.4B), and biotech (NEXGEL-Celularity tripling rev to $35M pro forma), signaling aggressive expansion amid positive sentiment in 70% of filings. Leadership churn affects 25+ companies with 15 appointments/promotions (e.g., Delek EVPs, Abacus CAO/CIO) vs 20 retirements/resignations (e.g., Voyager CFO, Rayonier CEO), mostly neutral but mixed in strategic pivots like Rayonier review. Financings surge with $250M+ raised via equity/debt (Prelude $90M, Surf Air $15M, Goldman Sachs $750M notes), while capital raises fund growth without major dividend/buyback shifts. Where PoP data available, revenue trends strong (CrowdStrike FY24 $3.06B to FY26 $4.81B +57%; NHI 2025 $39.7M lease rev lost post-sale), but outliers like Rigel collab termination flag risks. Portfolio-level: Small/mid-cap biotech/tech lead bullish catalysts (H2 2026 closes), deleveraging via asset sales (NHI $560M proceeds, 2.3x net D/E), no broad margin compression but unverified metrics in mining (Sow Good). Implications: Buy M&A targets/acquirers pre-close, monitor exec turnover for conviction, H2 catalysts could drive 10-20% sector pops.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 21, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream on April 21, 2026, dominant themes include heavy institutional accumulation in mega-cap tech stocks (Apple, Microsoft, NVIDIA, Alphabet) via 13F-HR disclosures from 16 managers totaling billions in AUM, signaling sustained conviction amid market rotations. Banking sector shows resilient YoY growth (e.g., United Community Banks +18% net income YoY, +12% revenue) but QoQ softness in income and rising provisions, with NIM expansions averaging +20 bps YoY. Healthcare mixed with UnitedHealth raising FY2026 adjusted EPS guidance to >$18.25 despite Optum dip, while tech/industrials highlight positive capital returns (AppLovin $2.2B buybacks, Delek dividend) and M&A (Onto Innovation $710M stake). SPAC IPO filings (AEI CapForce, Vernal, Collective, East West) indicate renewed blank-check activity with dilution risks and 18-24 month de-SPAC deadlines. Proxy statements cluster around June 2026 annual meetings, building a catalyst calendar. No widespread insider selling; instead, performance awards to execs (CrowdStrike, PPG) reflect alignment. Portfolio-level trends: 4/5 banks report YoY EPS growth averaging +15%, but 3 show QoQ net income declines; overall sentiment leans neutral-positive with mixed in financials.

17 high priority 33 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — April 21, 2026

The April 21, 2026, SEC filings reveal a surge in 13F-HR reports from 20+ institutions showcasing overwhelming conviction in mega-cap tech (Apple, NVDA, MSFT topping most portfolios) and broad ETFs, signaling portfolio-level bullishness on US equities amid market highs. Earnings releases show mixed financial/healthcare performance: Synchrony Financial +6% YoY net earnings with NIM stability and massive $6.5B buyback; UnitedHealth +2% YoY revenue, margin expansion, raised FY2026 EPS >$18.25; but Optum dip and First United loan stagnation highlight sector pressures. SPAC activity dominates with 10+ filings (e.g., Archimedes/Forge Nano $1.2B merger, Titan/Key Mining titanium project), pointing to M&A resurgence in tech/mining/quantum amid critical minerals demand. Capital returns accelerate (Synchrony 13% dividend hike, UNH $2B Q2 repurchase, News Corp $1B program), while risks emerge in consumer (Allbirds Q1 net loss $19.6M, gross margin 27.8%) and biotech (PAVmed going concern). Forward catalysts cluster in Q2: AGMs, SPAC closings, earnings calls. Overall, actionable alpha in SPACs/outliers like Onto Innovation's $710M Rigaku stake (accretive H2 2026) vs. deteriorating microcaps.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 21, 2026

Across 50 filings from the S&P 500 Consumer Discretionary stream, dominant themes include heavy institutional portfolio concentration in tech giants (AAPL, MSFT, NVDA across 25+ 13F-HRs totaling billions), mixed Q1 2026 financial performance in consumer-adjacent lenders with average NIM expansion of +25 bps YoY in 5 reporters (Hanmi +25bps QoQ, Northfield +38bps YoY) offset by NAV declines in BDCs (Onex -10% QoQ), and robust capital returns averaging $100M+ programs (Synchrony $6.5B buyback, Donnelley $150M). M&A activity persists with litigation risks (Farmer Bros 14 demands on Royal Cup merger) and SPAC dilutions (AEI CapForce NTBV $7.85 vs $10 IPO), while forward guidance holds steady amid macro pressures (Equifax FY revenue +10-12%). Portfolio-level trends show deposit growth in banks (+1.8% QoQ Hanmi, +8.4% ann. Northfield) but loan declines (-0.3% Hanmi, -5.1% ann. Northfield), signaling cautious lending. Consumer-facing signals mixed: Synchrony purchase volumes +6% YoY but charge-offs monitored monthly; furniture/retail exec departures (Bassett, Simply Good Foods). Implications favor dividend/buyback plays over growth, with catalysts in Q2 mergers/proxy votes.

8 high priority 42 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 21, 2026

Across 50 filings in the USA S&P 500 Healthcare intelligence stream (with heavy financial services crossover), Q1 2026 results for reporting companies show average revenue growth of ~8% YoY (range 2-23%, e.g., UNH +2%, ISRG +23%, Danaher +3.7%, MSCI +14%), mixed margins (expansions in UHC +40bps, NIM Hanmi 3.38%; compressions Optum +140bps cost ratio), and resilient earnings (avg +10% YoY). Healthcare standouts include ISRG's 17% procedure growth and Danaher's 11.5% biotech surge, offsetting UNH Optum softness; biotech catalysts like Inhibrx's 20% ORR emerge positively. Capital allocation skews bullish with 8+ buyback/div announcements (Synchrony $6.5B no expiry, UNH $2B Q2, Danaher no Q1 buys vs $1.1B prior). 20+ 13F filings reveal institutional tilt to ETFs (avg 60%+ allocation) and mega-caps (Apple/Microsoft/NVDA ubiquitous), signaling defensive positioning. Guidance mostly raised (UNH FY EPS >$18.25, Danaher $8.35-8.55), but Prudential's sales suspension extension flags Japan risks. Portfolio trend: Regional banks outperforming mega (NIM +48bps YoY Bridgewater vs Cap One -39bps QoQ), healthcare devices/biotech > providers.

6 high priority 44 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 21, 2026

Across 50 DEF 14A proxy statements filed around April 21, 2026, for US SEC-listed companies, a dominant theme is preparation for clustered 2026 annual meetings primarily June 1-16, featuring routine director elections (pluarlity or majority votes), say-on-pay advisory votes, auditor ratifications, and equity incentive plan expansions/amendments in 20+ filings signaling potential dilution risks. Where 2025 financial data is enriched, period-over-period trends reveal stark bifurcation: 9 companies reported robust revenue growth (e.g., AppLovin +70% YoY, Ligand +48% royalties YoY, LendingClub +33% originations YoY) driving positive sentiment, while 2 showed deterioration (Mercer net loss expanded to $(498)M YoY, Cherry Hill BVPS returns negative early quarters with dividend cut from $0.15 to $0.10). Capital allocation highlights shareholder returns via buybacks (AppLovin $2.2B, +$3.2B authorization) and dividends (Power Integrations +2.4% increase), with M&A catalysts like Odyssey's AOM merger (close late Q2/early Q3 2026) and BioMarin's acquisitions. No widespread insider trading data, but leadership transitions (e.g., CEOs in Amerant, Power Integrations) signal governance evolution; portfolio-level, biotech/pharma (12/50) and tech/advertising show outperformance vs. finance/REITs with mixed trends. Implications: Bullish for growth outliers pre-AGM rallies, caution on dilution-heavy plans and weak performers amid neutral sentiment in 70% of filings.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 21, 2026

The IPO Pipeline stream shows a cluster of four high-materiality filings on April 21, 2026, dominated by three S-1 registrations (two SPACs and one operating company), signaling a potential resurgence in blank-check and tech IPO activity amid neutral sentiment across all. Hall Chadwick and East West Ave SPACs feature standard $10/unit structures with sponsor/private commitments totaling millions in warrants/units, while Fusemachines discloses stable YoY customer/supplier concentration risks from 2024-2025 periods. Tecnoglass S-4 proxy emphasizes operational risks ahead of its 2026 AGM for Florida reincorporation and JV benefits with Saint-Gobain. No significant period-over-period financial trends emerge due to pre-IPO nature, but redemption scenarios up to 100% in SPACs highlight dilution risks; sponsor purchases indicate management skin-in-the-game. Market implications include near-term IPO pricing catalysts and watch for SPAC de-SPAC timelines within 24 months, positioning investors for early access to fresh capital raises totaling at least $265M.

4 high priority 4 total filings
· daily

Global High-Priority Regulatory Events — April 21, 2026

The 50 filings reveal a surge in M&A and SPAC activity, with 15+ deals including SoundHound AI's $43M acquisition of LivePerson (22% premium, debt-free post-close), Brady Corp's $1.4B Honeywell PSS buy (8x EBITDA, double-digit EPS accretive), and multiple SPAC mergers like Archimedes/Forge Nano ($1.2B equity value) and Titan/Key Mining ($303M), signaling bullish consolidation in AI, tech, mining, and critical minerals amid $500M+ revenue opportunities. Period-over-period trends show mixed financial health: revenue growth in GE Aerospace (+25% YoY to $12.4B), Danaher (+3.7% to $5.95B), and CMB.TECH (+16% to $1.89B), but margin compressions (GE -490bps GAAP profit margin, Danaher comprehensive income -75%), rising expenses (CMB vessel ops +111%), and deteriorations like Black Hawk net income -79% YoY. Insolvency risks persist in Quadrant Televentures and Setubandhan Infrastructure (CIRP ongoing, plans rejected), alongside delisting threats (Quetta Acquisition). Capital allocation favors buybacks (Aurobindo ₹800Cr, 0.93% shares) and repurchases (AppLovin $2.2B), with positive insider alignment via CrowdStrike's 100K PSUs to President. Sector themes highlight SPAC resurgence in quantum/biotech/healthcare and resource pivots (Sow Good graphite). Portfolio implications: overweight M&A catalysts H2 2026, monitor SPAC redemptions/delays, avoid insolvency-exposed names.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 21, 2026

Across 21 Q1 2026 filings, revenue growth was a dominant theme with 16/21 companies reporting YoY increases averaging +16% (led by GE Aerospace +24.7%, Range Resources +50%, Aircastle +18.8%), though profitability was mixed: 12/21 saw net income growth (avg +35% where positive) but 6 experienced declines (avg -45%), driven by higher expenses and one-offs. Margin compression appeared in 8/21 (e.g., GE Aerospace 26.4% vs 28.7%, 3M EPS -40%), offset by operational leverage in defense (Northrop op income +73%) and leasing (Aircastle EBITDA +19.7%). Capital allocation leaned shareholder-friendly with buybacks in 7/21 (total ~$1.5B, e.g., MSCI $414.8M, Pegasystems $167M) and dividend hikes in 5 (e.g., Northrop $2.31 vs $2.06, Range $0.10 vs $0.09), but cash burns persisted in 9/21 amid acquisitions/investments. Sector strength in aerospace/defense (GE, Northrop, RTX, Aircastle) and water/industrials (Zurn +11.4% sales), contrasted by weakness in small-caps (Fly-E -53% rev, Pacific negative sentiment). Implications: Bullish for large-cap industrials/defense on growth/margins; caution on micro-caps with cash depletion; portfolio rotation toward buyback-heavy names like MSCI/Equifax for near-term returns.

21 high priority 21 total filings
· daily

US SEC Trading Suspension Halt Orders — April 21, 2026

Nine Nasdaq-listed small-cap companies disclosed deficiency notices on April 16-20, 2026, primarily for late Form 10-K filings (6/9 cases: Atlantic American, Allied Gaming, Driven Brands, Laser Photonics, Society Pass, Aimei Health), with others citing bid price violation (Expensify), annual meeting delay (Fly-E Group), and low stockholders' equity (ENDRA Life Sciences); no immediate trading suspensions but delisting risks escalate with clustered compliance deadlines in June-October 2026. Sentiment is negative across 8/9 filings (materiality 9/10 for most), reflecting broad micro-cap distress from accounting delays, administrative lapses, and financial weaknesses. Driven Brands provides the only substantive period-over-period data, showing FY2025 SSS growth of 3.5%-3.7% (Driven) and 6.1%-6.2% (Take 5) vs flat Q4, revenue $1,850-$1,860M (stable YoY implied), Adjusted EBITDA $440-$450M (lower due to restatement), and net debt reduction 24% QoQ to $1.6B with net unit growth of 175 FY2025/29 Q1 2026. Laser Photonics stands out as resolved swiftly (10-K filed, matter closed April 21), while others plan filings/compliance by mid-June. Portfolio-level pattern: 67% tied to reporting failures, signaling sector-wide governance/audit issues; investors face heightened volatility from reverse splits, appeals, and potential OTC transfers. Key implication: Short-term shorts on unresolved names, watch for compliance bounces.

9 high priority 9 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 21, 2026

Across 45 filings in the USA Corporate Distress & Bankruptcy stream (33 new), small-cap distress dominates with 12 companies (e.g., Expensify, Atlantic American, Fly-E Group, Allied Gaming, Society Pass, ENDRA Life Sciences, Aimei Health) receiving Nasdaq deficiency notices for late 10-Ks, low bid prices (<$1), low equity (<$2.5M), or missed shareholder meetings, signaling widespread compliance risks and potential delistings by Q3/Q4 2026. Positive offsets include accretive M&A (SoundHound AI acquiring LivePerson at 22% premium for $500M rev opportunity; Brady acquiring Honeywell PSS at 8x EBITDA, double-digit EPS accretive; NHI divestiture deleveraging to 2.3x net debt/EBITDA) and financings ($90M Prelude Therapeutics offering, $15M Surf Air), but debt restructurings (Reborn Coffee forbearance, NKGen $40M consolidated note) highlight liquidity strains. Limited period data shows mixed trends: Driven Brands Q4 SSS flat (0.3-0.5%) vs FY +3.5-3.7%, Take 5 SSS Q4 +1% vs FY +6.2%; NHI loses $39.7M 2025 lease rev from divestiture. No insider selling clusters, but sparse activity (e.g., Howard Hughes director investing $10M warrants); forward guidance flags H2 2026 catalysts like deal closes (SOUN/LPSN, Onto/Rigaku 27% stake). Portfolio implication: Small-cap consolidation via M&A amid delisting pressures, favor deleveraging plays over compliance laggards.

45 high priority 45 total filings
· daily

US Executive Officer Management Changes SEC — April 21, 2026

Across 32 SEC filings on US executive and director changes dated April 21, 2026, the dominant theme is orderly leadership transitions, with 18 planned retirements/non-re-elections (e.g., CAVA, Radian, Xeris, CION, Trulieve, SandRidge) signaling proactive succession amid neutral sentiment, contrasted by 10 positive appointments/promotions (Delek, Abacus, Envoy, MGE Energy) bringing deep industry expertise. Limited period-over-period financials highlight CrowdStrike's exceptional growth (revenue +57% from $3.06B FY2024 to $4.81B FY2026, ARR +52% to $5.25B, 300% stock return in 95th percentile of S&P 500), while others show capital allocation via equity awards (CrowdStrike 100k PSUs targeting $20B ARR by ~2030, PPG $1.5M MSUs, MGE 25k RSUs) and Adobe's $25B buyback through 2030. Negative outliers include CTO termination at Airgain, chairman resignation over strategy at Lipocine (mixed sentiment), board death at Enigma-Bulwark, and key departures at Masco/Voyager/Timken without immediate successors. Portfolio-level patterns reveal strong AGM support (HP 73.6M-share plan approved, PPG/Warrior unanimous), biotech leadership refreshes (Sagimet/Voyager CMO/CFO shifts), and severance enhancements (Virgin Galactic, Cerus, Robert Half amendments), implying management alignment but watch for execution risks. Market implications favor stability in tech/biotech with growth catalysts, caution in industrials/energy on leadership gaps.

32 high priority 32 total filings